Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
OpenAI Rejects Apple Trade Secret Theft Claims 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Xiaomi Shares Jump on Europe EV Expansion Plan 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
Tesla Cybercab Rides Launch in Austin as NHTSA Reviews Rollout 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
Add as a preferred source on Google
NOVATO, Calif., March 08, 2018 -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, will present at the following investor conferences:
- Emil D. Kakkis, M.D., Ph.D., the company’s Chief Executive Officer, will present at the Barclays Global Healthcare Conference on Tuesday, March 13, 2018 at 8:00 am ET in Miami.
- Shalini Sharp, the company's Chief Financial Officer, will present at the Cowen Healthcare Conference on Tuesday, March 13, 2018 at 8:40 am ET in Boston.
The live and archived webcast of the company presentations will be accessible from the company’s website at http://ir.ultragenyx.com/events.cfm. The replay of the webcast will be available for 90 days.
About Ultragenyx
Ultragenyx is a biopharmaceutical company committed to bringing to patients novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company’s website at www.ultragenyx.com.
Contact Ultragenyx Pharmaceutical Inc.
Investors & Media
Danielle Keatley
415-475-6876
